论文部分内容阅读
目的观察熊去氧胆酸治疗原发性胆汁性肝硬化的临床疗效。方法 40例原发性胆汁性肝硬化患者,抗线粒体抗体(AMA)和抗线粒体抗体-M2(AMA-M2)均阳性,经熊去氧胆酸持续治疗时间0.5～5(平均1.8)a,观察临床表现,肝功能生化指标血清丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、白蛋白(Alb)、总胆红素(TBil)、碱性磷酸酶(AKP)和r-谷氨酰转酞酶(r-GT)等变化。结果所有患者经熊去氧胆酸治疗后,临床症状明显改善,肝功能ALT、AST、TBil、AKP和r-GT明显下降(均P<0.01),Alb升高(P<0.01)。患者在治疗中无明显药物不良反应和死亡发生。结论熊去氧胆酸长期治疗原发性胆汁性肝硬化,能有效减轻和控制症状,改善肝功能生化指标,减缓病情进展。
Objective To observe the clinical efficacy of ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Methods Forty patients with primary biliary cirrhosis were positive for anti-mitochondrial antibody (AMA) and anti-mitochondrial antibody-M2 (AMA-M2). The duration of ursodeoxycholic acid treatment was 0.5-5 (average 1.8) The clinical manifestations, serum biochemical indicators of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (Alb), total bilirubin (TBil), alkaline phosphatase ) And r-glutamyl transpeptidase (r-GT) and other changes. Results All patients were treated with ursodeoxycholic acid, and the clinical symptoms were significantly improved. The ALT, AST, TBil, AKP and r-GT were significantly decreased (all P <0.01) and Alb increased (P <0.01). Patients in the treatment of no obvious adverse drug reactions and death occurred. Conclusion Ursodeoxycholic acid long-term treatment of primary biliary cirrhosis, can effectively reduce and control symptoms, improve biochemical markers of liver function, slow the progression of the disease.